Nektar Therapeutics is a biopharmaceutical company engaged in the development of novel therapeutics based on the company’s PEGylation and advanced polymer conjugation technology platforms. The company’s R&D pipeline consists of potentially high-value therapeutics in pain, oncology and other therapeutic areas. NKTR’s proprietary candidate, NKTR-181, is a novel mu-opioid analgesic in phase 2 development in osteoarthritis patients with chronic knee pain. For more information, visit the company’s Web site: http://www.nektar.com
Let us hear your thoughts below: